Viemed Healthcare | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 78.1 M

Revenue: As of FY2026 Q2, the actual value is USD 78.1 M, beating the estimate of USD 78 M.

EPS: As of FY2026 Q2, the actual value is USD 0.07, missing the estimate of USD 0.12.

EBIT: As of FY2026 Q2, the actual value is USD 4.709 M.

Financial Highlights for Three Months Ended June 30, 2026 (Q2 2026)

Revenue

Viemed Healthcare, Inc. reported record net revenues of $78.1 million, an increase of $15.0 million, or 23.9%, compared with the prior-year quarter, and approximately 3.6% sequentially. Total revenues for the quarter were $78,097 thousand.

Segment Revenue (Q2 2026, in thousands of U.S. Dollars)

• Rental Revenue
  • Ventilators, non-invasive & invasive: $36,411
  • Other home medical equipment rentals: $16,408
• Sales & Service Revenue
  • Equipment and supply sales: $18,971
  • Service revenues: $6,307

Net Income

Net income attributable to Viemed Healthcare, Inc. totaled $2.8 million, or $0.07 per diluted share. Net Income attributable to Viemed Healthcare, Inc. for Q2 2026 was $2,764 thousand.

Gross Profit

Gross profit for the quarter was $45,048 thousand, compared to $36,731 thousand for the same period in 2025. The gross profit margin was 58%.

Income from Operations

Income from operations was $4,461 thousand, down from $5,095 thousand in the prior-year quarter.

Adjusted EBITDA

Adjusted EBITDA for the quarter totaled $13.7 million, a 4.0% decrease as compared to the quarter ended June 30, 2025. Adjusted EBITDA totaled $13,715 thousand, representing a 4% decrease year-over-year.

Cash Flow

Net cash provided by operating activities totaled $15.9 million for the quarter and $60.8 million for the trailing twelve months ended June 30, 2026. For the six months ended June 30, 2026, net cash provided by operating activities was $23,973 thousand, up from $15,108 thousand in the same period of 2025. Free cash flow totaled $8.6 million for the quarter and $34.4 million for the trailing twelve months ended June 30, 2026.

Balance Sheet (as of June 30, 2026)

Viemed Healthcare, Inc. maintained a cash balance of $10.7 million. Cash and Cash Equivalents were $10,680 thousand. The company had an overall working capital balance of $6.1 million. Working Capital stood at $6,072 thousand. Long-term debt totaled $6.4 million. Long Term Debt was $6,374 thousand. The company had $46 million in unfunded commitments available under its existing credit facilities.

Share Repurchase

During the second quarter of 2026, Viemed Healthcare, Inc. repurchased and cancelled 530,802 common shares under its share repurchase program at a cost of $5.1 million (excluding taxes), representing an average buyback price of $9.65 per share.

Capital Expenditures and Allocation

Net capital expenditures totaled $7.3 million, or 9.3% of revenue, for Q2 2026. First-half net capital expenditures were $12.8 million, or 8.3% of revenue. The company reduced debt through $2.2 million of term loan repayments.

Operational Metrics for Three Months Ended June 30, 2026 (Q2 2026)

Ventilator Patients

Viemed Healthcare, Inc. ended the second quarter of 2026 with a record 12,635 ventilator patients, an increase of 4.0% over June 30, 2025, and a 4.5% sequential increase from March 31, 2026. This represents the highest census in company history.

PAP Therapy Patient Count

The company increased its PAP therapy patient count to 37,825, an increase of 44.0% over June 30, 2025, and a 5.3% sequential increase from March 31, 2026.

Sleep Resupply Patient Count

The company’s sleep resupply patient count was 37,035, up 46.7% year over year and 10.0% sequentially.

Full Year 2026 Guidance

Viemed Healthcare, Inc. raised the low end and narrowed its full-year net revenue guidance to a range of $314 million to $320 million, compared with the previous range of $312 million to $320 million. Adjusted EBITDA is now expected to range from $64 million to $68 million, revised from the previous range of $65 million to $69 million. Net capital expenditures are now expected to range from 8.5% to 10.0% of net revenue, a decrease from the previous range of 9.0% to 10.5%, reflecting a growing contribution from less capital-intensive product and service revenue.